DEA Proposes Schedule I Placement for Diphenidine: What Healthcare Operators Need to Know

What this means for your practice

Diphenidine is not a substance currently used in standard clinical or telehealth practice, so most healthcare operators will face no direct prescribing or dispensing impact from this proposed rule. However, compliance teams at telehealth platforms, compounding pharmacies, research-adjacent facilities, and any organization conducting chemical analysis should review their substance inventories and research protocols to confirm diphenidine is not handled without appropriate DEA registration. The comment period closes June 25, 2026, giving stakeholders a narrow window to submit formal input if their operations could be affected. More broadly, this action is a reminder that the DEA's scheduling authority under the CSA is actively expanding — and that any novel or research-chemical compound in your formulary or lab inventory warrants proactive regulatory review before enforcement actions arise.

DEA Proposes Schedule I Placement for Diphenidine

The Drug Enforcement Administration (DEA) has published a Notice of Proposed Rulemaking (NPRM) in the Federal Register proposing to place diphenidine — chemically identified as 1-(1,2-diphenylethyl)piperidine — in Schedule I of the Controlled Substances Act (CSA). The proposal covers the substance's salts, isomers, and salts of isomers wherever such forms are chemically possible.

Docket No. DEA-1155 governs this rulemaking, which appears at 21 CFR Part 1308.

What Is Diphenidine?

Diphenidine is a dissociative compound belonging to the diarylethylamine chemical class. The source document does not characterize it as having any approved medical use, which is consistent with Schedule I placement criteria under the CSA. The DEA's proposed action is driven in part by the United States' obligations under the 1971 Convention on Psychotropic Substances, an international treaty framework that coordinates global scheduling of psychoactive substances.

What Schedule I Classification Means

Under the Controlled Substances Act, Schedule I substances are those determined to have:

• No currently accepted medical use in the United States
• A high potential for abuse
• A lack of accepted safety for use under medical supervision

If this proposed rule is finalized, the full regulatory weight of Schedule I would apply to diphenidine. According to the DEA's proposed rule, this includes administrative, civil, and criminal sanctions for persons who:

• Manufacture or distribute diphenidine
• Import or export diphenidine
• Engage in research or instructional activities involving diphenidine
• Conduct chemical analysis using diphenidine
• Possess diphenidine

This means that any entity wishing to handle diphenidine after finalization would need to obtain the appropriate DEA Schedule I researcher registration — a process that is separate from, and more restrictive than, standard practitioner or dispensing registrations.

Comment Period and Hearing Requests

The DEA has opened a public comment period, with all comments due on or before June 25, 2026. Comments may be submitted electronically via www.regulations.gov under Docket No. DEA-1155.

Interested parties may also file a request for a hearing or a waiver of hearing under 21 CFR 1308.44, in accordance with 21 CFR 1316.47 and/or 1316.49. Hearing requests must also be received by June 25, 2026, and should be directed to the DEA Administrator at 8701 Morrissette Drive, Springfield, Virginia 22152.

Organizations with a legitimate interest in the scheduling of this compound — including research institutions, academic medical centers, or compounders with novel substance research programs — should consult legal counsel and consider submitting formal comments or requesting a hearing before the deadline.

Implications for Telehealth, Medspas, and Clinical Operators

For the vast majority of telehealth brands, medspas, dental practices, and chiropractic offices, diphenidine is not part of any current clinical formulary, and this proposed rule will have no direct operational impact on prescribing, dispensing, or patient care workflows.

However, several categories of operators should pay attention:

1. Compounding Pharmacies and Research-Adjacent Facilities Any facility that handles novel or experimental compounds — even in trace quantities for research or analytical purposes — should audit current inventories to confirm diphenidine is not present. If it is, contact DEA's Diversion Control Division immediately to assess registration requirements.

2. Telehealth Platforms with Expanding Formularies As telehealth companies expand into wellness, mental health, and novel therapeutics, the DEA's active scheduling pipeline becomes increasingly relevant. Compounds that exist in gray regulatory zones today can shift to full Schedule I restrictions with relatively short notice through the NPRM process.

3. Any Entity Subject to DEA Registration This rulemaking is a reminder that DEA registration compliance is not static. The scheduled substances list evolves, and compliance programs should include mechanisms to monitor Federal Register scheduling actions on a routine basis.

The Bigger Regulatory Picture

This proposed rule reflects the DEA's ongoing use of the CSA scheduling process to bring novel psychoactive substances (NPS) under federal control — often in parallel with international treaty commitments. The 1971 Convention on Psychotropic Substances, administered through the United Nations, creates affirmative obligations for the U.S. to schedule certain compounds domestically when they are internationally controlled.

Healthcare compliance teams should treat this action as part of a broader pattern: the DEA is actively monitoring novel compounds and moving them through the scheduling process. Organizations that handle any research chemicals, investigational substances, or compounds not yet on the CSA schedules should maintain a proactive monitoring posture.

Key Dates and Action Items

| Item | Deadline / Detail | |---|---| | Comment Period Closes | June 25, 2026 | | Hearing Request Deadline | June 25, 2026 | | Docket Number | DEA-1155 | | CFR Citation | 21 CFR Part 1308 | | Submit Comments | regulations.gov |

Recommended actions for compliance teams: - Confirm diphenidine is not present in any formulary, research inventory, or analytical supply chain - Flag this docket for monitoring through finalization - If your organization has any interest in the scheduling outcome, engage counsel and submit comments before June 25, 2026 - Update internal substance monitoring protocols to include Federal Register NPRM tracking for Schedule I actions

Source: DEA — Proposed Rule: Schedules of Controlled Substances: Placement of Diphenidine in Schedule I · 2026-05-26